Immediate Impact of Ultrasound-Guided Prostate Biopsies on PCA3 Score

European Urology

Volumn 57, Issue 6, 2010, Pages 1121-1122

  Larré, Stéphane ^a   Ronsin, Christophe ^b   Irani, Jacques ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Biomnis   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LETTER; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; REPRODUCIBILITY; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GENE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951621433     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.02.036     Document Type: Letter

References (5)

1. Kirby R.S., Fitzpatrick J.M., and Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 103 (2009) 441-445
2. Lechevallier E., Echazarian C., Ortega J.C., et al. Kinetics of postbiopsy levels of serum free prostate-specific antigen and percent free prostate-specific antigen. Urology 53 (1999) 731-735
3. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
4. Haese A., De La Taille A., Van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
5. Sokoll Lj, Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389 (2008) 1-6